230 related articles for article (PubMed ID: 21569645)
1. [Efficacy and safety of rh-endostatin combined with chemotherapy versus chemotherapy alone for advanced NSCLC: a meta-analysis review].
Cao D; Ge W; Wang H; Zhang L; Zheng Y; Zhang J
Zhongguo Fei Ai Za Zhi; 2011 May; 14(5):404-13. PubMed ID: 21569645
[TBL] [Abstract][Full Text] [Related]
2. Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis.
Ge W; Cao DD; Wang HM; Jie FF; Zheng YF; Chen Y
Asian Pac J Cancer Prev; 2011; 12(10):2705-11. PubMed ID: 22320978
[TBL] [Abstract][Full Text] [Related]
3. Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis.
Ge W; Cao DD; Wang HM; Jie FF; Zheng YF; Chen Y
Asian Pac J Cancer Prev; 2011; 12(11):2901-7. PubMed ID: 22393961
[TBL] [Abstract][Full Text] [Related]
4. Endostar (rh-endostatin) versus placebo in combination with vinorelbine plus cisplatin chemotherapy regimen in treatment of advanced non-small cell lung cancer: A meta-analysis.
An J; Lv W
Thorac Cancer; 2018 May; 9(5):606-612. PubMed ID: 29575575
[TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of recombinant human endostatin combined with NP regimen for treating non-small cell lung cancer.
Gao C; Gao C; Yuan Q
Medicine (Baltimore); 2024 May; 103(21):e38027. PubMed ID: 38788043
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer.
Liu X; Guo Z; Su L; Zuo A; Gao M; Ji X; Lu J; Yang S; Jiang Y; Lu D
Invest New Drugs; 2024 Jun; 42(3):309-317. PubMed ID: 38700579
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
8. Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer.
Wang Z; Zhang H; Zhou C; Long X; Guan R; Yang N; Zhang Y
Cancer Med; 2019 Apr; 8(4):1434-1441. PubMed ID: 30762300
[TBL] [Abstract][Full Text] [Related]
9. Rh-endostatin Concomitant with Chemotherapy Versus Single Agent Chemotherapy for Treating Soft Tissue and Bone Sarcomas: A Systematic Review and Meta-Analysis.
Ma Z; Guo L; Cui X; Liu H; Liu L
J Pharm Pharm Sci; 2018; 21(1):386-397. PubMed ID: 30352660
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy.
Zhou S; Zuo L; He X; Pi J; Jin J; Shi Y
Thorac Cancer; 2018 Nov; 9(11):1354-1360. PubMed ID: 30152052
[TBL] [Abstract][Full Text] [Related]
11. Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies.
Wang B; Xu L; Li Q; Man S; Jin C; Liu L; Zhan S; Ning Y
BMC Cancer; 2020 Oct; 20(1):1021. PubMed ID: 33087103
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of circulating endothelial cells for efficacy of chemotherapy with Rh-endostatin in non-small cell lung cancer.
Liu ZJ; Wang J; Wei XY; Chen P; Wang LC; Lin L; Sun BC; Li K
J Cancer Res Clin Oncol; 2012 Jun; 138(6):927-37. PubMed ID: 22331237
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer.
Zhao X; Mei K; Cai X; Chen J; Yu J; Zhou C; Li Q
Invest New Drugs; 2012 Jun; 30(3):1144-9. PubMed ID: 21225314
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer.
Zhu J; Chen G; Niu K; Feng Y; Xie L; Qin S; Wang Z; Li J; Lang S; Zhuo W; Chen Z; Sun J
Future Oncol; 2022 Mar; 18(9):1077-1087. PubMed ID: 34986655
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis.
Feng L; Wang Z; Jing L; Zhou Z; Shi S; Deng R; Liu Y; Meng Q
World J Surg Oncol; 2021 Feb; 19(1):64. PubMed ID: 33637113
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer.
Fu S; Huang H; Shang K; Tu G; Zhong P; Li S; Zhu X; Peng S; Liu Y; Lu Z; Chen L
Future Oncol; 2023 Jan; 19(2):147-158. PubMed ID: 36779488
[TBL] [Abstract][Full Text] [Related]
18. [Vinorelbine plus oxaliplatin versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: a systematic review].
Liu X; Ma L; Yang K; Tian J
Zhongguo Fei Ai Za Zhi; 2010 Feb; 13(2):112-7. PubMed ID: 20673502
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study.
Wang ZQ; Wang DS; Wang FH; Ren C; Tan Q; Li YH
Invest New Drugs; 2021 Apr; 39(2):516-523. PubMed ID: 33070249
[TBL] [Abstract][Full Text] [Related]
20. Assessment on the Efficacy and Safety of Aidi Injection Combined with Vinorelbine and Cisplatin for Treatment of Advanced Nonsmall Cell Lung Cancer.
Zhao HY; Zhou HY; Wang YT; Chen W; Qi SY; Cao JL; Li GH
Chin Med J (Engl); 2016 Mar; 129(6):723-30. PubMed ID: 26960377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
